Stories

Prime Therapeutics recognized as Star Tribune National Standard Top Workplace

The Minneapolis Star Tribune recently named Prime Therapeutics a 2021 National Standard Top Workplace

June 21, 2021
This award recognizes the best places to work according to a company’s employees. The recognition was granted based on Prime’s benefit programs and offerings, community involvement opportunities and overall culture. It is also reflective of a progressive and innovative company mindset.

“We are proud to once again be named a Star Tribune Top Workplace,” says Erin Feigal, chief human resources officer. “We have a top-notch culture at Prime, and it’s great to see that our employees believe that too. Thank you to all of our employees – you make Prime an excellent place to work.”

The results were based on a voluntary employee survey that measures employee engagement and satisfaction, as well as organizational health.

This marks Prime’s eighth time to earn a spot on one of the Star Tribune’s Top Workplaces lists. This is the second time Prime has been honored this year, having been recognized nationally as a 2021 Top Workplace USA in January.

See a listing of the 2021 national standard setters

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Read More

Stories

July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend

Read More

Stories

July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion

Read More
View all news